SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results

被引：2

作者：

Starodub, Alexander N. ^{[1
]}

Ocean, Allyson J. ^{[2
]}

Shah, Manish A. ^{[2
]}

Vahdat, Linda T. ^{[2
]}

Chuang, Ellen ^{[2
]}

Guarino, Michael J. ^{[3
]}

Picozzi, Vincent J. ^{[4
]}

Thomas, Sajeve S. ^{[5
]}

Maliakal, Pius P. ^{[6
]}

Govindan, Serengulam V. ^{[6
]}

Wegener, William A. ^{[6
]}

Sharkey, Robert M. ^{[6
]}

Goldenberg, David M. ^{[7
]}

机构：

[1] Indiana Univ, Hlth Ctr Canc Care, Goshen, IA USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Helen F Graham Canc Ctr, Newark, DE USA

[4] Virginia Mason Canc Ctr, Seattle, WA USA

[5] MD Anderson Canc Ctr Orlando, Orlando, FL USA

[6] Immunomed Inc, Morris Plains, NJ USA

[7] Garden State Canc Ctr, Morris Plains, NJ USA

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-CT206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT206

引用

页数：1

共 44 条

[31] Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
Perrone, Emanuele
Lopez, Salvatore
Zeybek, Burak
Bellone, Stefania
Bonazzoli, Elena
Pelligra, Silvia
Zammataro, Luca
Manzano, Aranzazu
Manara, Paola
Bianchi, Anna
Buza, Natalia
Tymon-Rosario, Joan
Altwerger, Gary
Han, Chanhee
Menderes, Gulden
Ratner, Elena
Silasi, Dan-Arin
Azodi, Masoud
Hui, Pei
Schwartz, Peter E.
Scambia, Giovanni
Santin, Alessandro D.
FRONTIERS IN ONCOLOGY, 2020, 10
[32] Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Gray, Jhanelle E.
Heist, Rebecca S.
Starodub, Alexander N.
Camidge, D. Ross
Kio, Ebenezer A.
Masters, Gregory A.
Purcell, W. Thomas
Guarino, Michael J.
Misleh, Jamal
Schneider, Charles J.
Schneider, Bryan J.
Ocean, Allyson
Johnson, Tirrell
Gandhi, Leena
Kalinsky, Kevin
Scheff, Ronald
Messersmith, Wells A.
Govindan, Serengulam V.
Maliakal, Pius P.
Mudenda, Boyd
Wegener, William A.
Sharkey, Robert M.
Goldenberg, David M.
CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5711 - 5719
[33] Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
Cardillo, Thomas M.
Sharkey, Robert M.
Rossi, Diane L.
Arrojo, Roberto
Mostafa, Ali A.
Goldenberg, David M.
CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3405 - 3415
[34] Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience
Starodub, Alexander
Ocean, Allyson J.
Messersmith, Wells A.
Picozzi, Vincent J.
Guarino, Michael J.
Bardia, Aditya
Thomas, Sajeve Samuel
Berlin, Jordan
Shah, Manish A.
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[35] Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
Dotan, Efrat
Cohen, Steven J.
Starodub, Alexander N.
Lieu, Christopher H.
Messersmith, Wells A.
Guarino, Michael J.
Marshall, John L.
Goldberg, Richard M.
Hecht, J. Randolph
Maliakal, Pius
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Lee, Lucy
Goldenberg, David M.
Berlin, Jordan D.
CANCER RESEARCH, 2016, 76
[36] ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting low HER2-expressing solid cancers
Zammarchi, F.
Chivers, S.
Williams, D. G.
Adams, L.
Mellinas-Gomez, M.
Tyrer, P.
Corbett, S.
D'Hooge, F.
Dissanayake, S.
Sims, S.
Havenith, K.
Howard, P. W.
Hartley, J. A.
Van Berkel, P. H.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S28 - S28
[37] First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Starodub, Alexander N.
Ocean, Allyson J.
Shah, Manish A.
Guarino, Michael J.
Picozzi, Vincent J., Jr.
Vahdat, Linda T.
Thomas, Sajeve S.
Govindan, Serengulam V.
Maliakal, Pius P.
Wegener, William A.
Hamburger, Steven A.
Sharkey, Robert M.
Goldenberg, David M.
CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3870 - 3878
[38] DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Marathe, O.
Cheng, Y.
Spira, A. I.
Hamilton, E. P.
Rubinstein, M. M.
Dong, X.
Li, L.
Lv, D.
Shi, J.
Gabrail, N.
Amin, H.
Wu, C.
Zhu, Z.
Qiu, Y.
Gu, V.
Qiu, X.
Shi, R.
Liu, L.
Miao, P.
Ueno, N. T.
ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
[39] A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study.
Dotan, Efrat
Starodub, Alexander
Berlin, Jordan
Lieu, Christopher Hanyoung
Guarino, Michael J.
Marshall, John
Hecht, J. Randolph
Cohen, Steven J.
Messersmith, Wells A.
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Goldenberg, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Jhaveri, K.
Han, H.
Dotan, E.
Oh, D-Y.
Ferrario, C.
Tolcher, A.
Lee, K-W.
Liao, C-Y.
Kang, Y-K.
Kim, Y. H.
Hamilton, E.
Spira, A.
Patel, N.
Karapetis, C.
Rha, S. Y.
Boyken, L.
Woolery, J.
Bedard, P.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S749 - S750

← 1 2 3 4 5 →